Derudover sås cholelithiasis som følge af udfældning af sulfatkonjugater af hydroxymetabolitter af aripiprazol i galden hos aber efter gentagne orale doser på 25- 125 mg/ kg/ dag (1- 3 gange middel - steady- state AUC ved den maksimale, anbefalede kliniske dosis eller 16- 81 gange den anbefalede, humane dosis baseret på mg/ m2).
An additional finding was cholelithiasis as a consequence of precipitation of sulphate conjugates of hydroxy metabolites of aripiprazole in the bile of monkeys after repeated oral dosing at 25 to 125 mg/ kg/ day (1 to 3 times the mean steady-state AUC at the maximum recommended clinical dose or 16 to 81 times the maximum recommended human dose based on mg/ m2).